EIZO (6737) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
18 Mar, 2026Executive summary
Net sales for the quarter ended June 30, 2024, declined 1.9% year-over-year to JPY18.1B, with operating income dropping sharply to JPY0.06B, reflecting weak demand in key segments and higher costs.
Net income fell 57.9% year-over-year to JPY0.7B, despite a JPY0.3B foreign exchange gain.
Comprehensive income rose to JPY6.8B, up 22.5% year-over-year, driven by gains in other comprehensive income.
Financial highlights
Net sales: JPY18.1B (98.1% YoY), gross profit: JPY5.8B (92.3% YoY), gross margin: 32.1% (down 2.0pt YoY).
Operating income: JPY0.06B (5.4% YoY), net income: JPY0.7B (42.1% YoY), ordinary income: JPY1.0B (39.9% YoY).
SG&A expenses rose 9.7% YoY to JPY5.8B, driven by wage increases and R&D investment.
Earnings per share for the quarter were JPY35.28, compared to JPY83.80 in the prior year.
Total assets increased to JPY172.0B as of June 30, 2024, from JPY164.8B at March 31, 2024.
Outlook and guidance
No revision to full-year FY2024 guidance: net sales JPY85.0B (+5.6% YoY), operating income JPY5.5B (+40.7% YoY), net income JPY5.0B (-8.3% YoY).
Earnings per share forecast for the year is JPY121.50, reflecting a 2-for-1 share split.
FX sensitivity: JPY1 depreciation impacts operating income by -JPY70M (USD) and +JPY140M (EUR).
Latest events from EIZO
- Profits and comprehensive income fell sharply, with a modest sales outlook and share split enacted.6737
Q2 202518 Mar 2026 - Profits dropped despite stable sales, with unchanged guidance and a recent share split.6737
Q3 202518 Mar 2026 - Flat sales and lower profit, but FY2026 outlook targets growth and higher dividends.6737
Q4 202518 Mar 2026 - Sales and profits fell on European weakness, but margin and new products support future outlook.6737
Q1 202618 Mar 2026 - Healthcare and Amusement drove 2.9% sales growth, but profits were pressured by higher SG&A.6737
Q2 202618 Mar 2026 - Net sales rose, but profit outlook was cut due to higher costs and weak European demand.6737
Q3 202618 Mar 2026